Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) dropped 2.1% on Friday . The company traded as low as $13.57 and last traded at $14.65, with a volume of 52,855 shares. The stock had previously closed at $14.97.

CRVS has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Monday, June 20th. BTIG Research initiated coverage on shares of Corvus Pharmaceuticals in a research note on Thursday, June 2nd. They set a “buy” rating on the stock. Cantor Fitzgerald started coverage on shares of Corvus Pharmaceuticals in a research note on Monday, April 18th. They set a “buy” rating and a $23.00 price target on the stock. Guggenheim started coverage on Corvus Pharmaceuticals in a report on Monday, April 18th. They set a “buy” rating and a $24.00 price objective for the company. Finally, Credit Suisse Group AG started coverage on Corvus Pharmaceuticals in a report on Monday, April 18th. They set an “outperform” rating and a $25.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, Corvus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $21.60.

The stock’s 50-day moving average price is $13.68 and its 200 day moving average price is $13.64. The company’s market capitalization is $298.95 million.

In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller purchased 30,300 shares of the company’s stock in a transaction that occurred on Friday, May 13th. The shares were acquired at an average price of $10.00 per share, for a total transaction of $303,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder A/S Novo purchased 70,000 shares of the company’s stock in a transaction that occurred on Thursday, May 12th. The stock was acquired at an average price of $10.00 per share, for a total transaction of $700,000.00. Following the purchase, the insider now owns 3,224,046 shares in the company, valued at approximately $32,240,460. The disclosure for this purchase can be found here.

Corvus Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.